Profile data is unavailable for this security.
About the company
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).
- Revenue in USD (TTM)87.64m
- Net income in USD15.79m
- Incorporated2006
- Employees110.00
- LocationPrecision BioSciences Inc302 E Pettigrew St Ste A100DURHAM 27701-2393United StatesUSA
- Phone+1 (919) 314-5512
- Fax+1 (480) 393-5553
- Websitehttps://precisionbiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rapt Therapeutics Inc | 0.00 | -120.43m | 63.52m | 122.00 | -- | 0.5816 | -- | -- | -3.12 | -3.12 | 0.00 | 3.13 | 0.00 | -- | -- | 0.00 | -69.23 | -46.30 | -75.81 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Vor Biopharma Inc | 0.00 | -118.09m | 63.90m | 168.00 | -- | 0.6511 | -- | -- | -1.74 | -1.74 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -60.16 | -45.79 | -64.52 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Gritstone bio Inc | 14.61m | -133.03m | 64.77m | 231.00 | -- | 2.91 | -- | 4.43 | -1.35 | -1.35 | 0.1391 | 0.1884 | 0.08 | -- | 49.20 | 63,251.08 | -72.86 | -48.08 | -83.37 | -55.18 | -- | -- | -910.50 | -573.71 | -- | -97.11 | 0.6461 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 24.12m | -21.25m | 64.92m | 81.00 | -- | 0.5877 | -- | 2.69 | -0.3869 | -0.3869 | 0.436 | 2.00 | 0.1826 | -- | -- | 297,728.40 | -16.09 | -66.24 | -17.73 | -71.36 | -- | -- | -88.10 | -- | -- | -- | 0.0029 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
| Maia Biotechnology Inc | 0.00 | -28.08m | 66.94m | 13.00 | -- | 21.02 | -- | -- | -1.62 | -1.62 | 0.00 | 0.1332 | 0.00 | -- | -- | 0.00 | -251.96 | -- | -362.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
| Vivani Medical Inc | 0.00 | -24.20m | 67.41m | 44.00 | -- | 2.83 | -- | -- | -0.4643 | -0.4643 | 0.00 | 0.4316 | 0.00 | -- | -- | 0.00 | -44.89 | -56.58 | -50.97 | -67.66 | -- | -- | -- | -2,868.72 | -- | -- | 0.00 | -- | -- | -- | -84.69 | -- | 40.33 | -- |
| Immuneering Corp | 0.00 | -56.07m | 67.61m | 66.00 | -- | 1.02 | -- | -- | -1.91 | -1.91 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -55.52 | -- | -59.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -20.60m | 67.98m | 31.00 | -- | 1.77 | -- | -- | -1.43 | -1.43 | 0.00 | 2.88 | 0.00 | -- | -- | 0.00 | -56.37 | -58.43 | -59.43 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Precision BioSciences Inc | 87.64m | 15.79m | 69.44m | 110.00 | -- | 0.9153 | 3.32 | 0.7924 | -0.1363 | 0.202 | 17.59 | 10.49 | 0.5044 | -- | 79.03 | 804,036.70 | 9.09 | -35.35 | 12.24 | -44.22 | -- | -- | 18.02 | -147.50 | -- | -- | 0.2314 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| MDxHealth SA | 80.74m | -40.80m | 70.13m | 300.00 | -- | -- | -- | 0.8686 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| OS Therapies Inc | 0.00 | -6.55m | 70.57m | 4.00 | -- | -- | -- | -- | -0.3011 | -0.3011 | 0.00 | -1.32 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.9763 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
| Spero Therapeutics Inc | 118.46m | 17.46m | 72.43m | 46.00 | 4.23 | 0.899 | 4.11 | 0.6114 | 0.3169 | 0.3169 | 2.21 | 1.49 | 0.9524 | -- | 4.11 | 2,575,196.00 | 14.03 | -35.52 | 18.79 | -41.75 | -- | -- | 14.74 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | 57.92m | 73.82m | 17.00 | 1.15 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
| Ovid Therapeutics Inc | 567.53k | -29.75m | 75.23m | 40.00 | -- | 0.8462 | -- | 132.56 | -0.4218 | -0.4218 | 0.008 | 1.25 | 0.0045 | -- | -- | 14,188.25 | -23.39 | -20.78 | -25.86 | -23.27 | -- | -- | -5,241.56 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Armata Pharmaceuticals Inc | 3.72m | -67.04m | 75.98m | 66.00 | -- | -- | -- | 20.43 | -1.95 | -1.95 | 0.0893 | -1.28 | 0.0355 | -- | 0.7532 | 56,348.48 | -64.00 | -59.78 | -385.50 | -72.70 | -- | -- | -1,802.72 | -1,113.72 | -- | -1.99 | 1.71 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
Data as of Sep 19 2024. Currency figures normalised to Precision BioSciences Inc's reporting currency: US Dollar USD
39.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 633.13k | 8.75% |
| Tang Capital Management LLCas of 30 Jun 2024 | 623.33k | 8.62% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 426.29k | 5.89% |
| Aquilo Capital Management LLCas of 30 Jun 2024 | 381.80k | 5.28% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 259.71k | 3.59% |
| Alyeska Investment Group LPas of 30 Jun 2024 | 176.38k | 2.44% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 110.77k | 1.53% |
| Citadel Advisors LLCas of 30 Jun 2024 | 97.28k | 1.35% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 83.00k | 1.15% |
| Moloney Securities Asset Management LLCas of 30 Jun 2024 | 49.20k | 0.68% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
